Breast cancer (BC) treatment relies on the expression of ERα to implement endocrine therapy (ET), which targets various aspects of 17β-estradiol (E2):ERα signaling to inhibit cell proliferation and limit tumor progression. Here, ESR1 is linked to neoplasm.